stents

Very Late Thrombosis in Bioresorbable Scaffolds

The presence of a metallic device interrupts normal laminar flow and creates an artery environment that favors thrombosis, leaving the vessel vulnerable to very late thrombosis. Dual antiplatelet therapy, a better implantation technique, and several improvements in new drug-eluting stents (DES) (thinner struts, and higher polymer stability and biocompatibility) have lowered significantly the incidence of<a href="https://solaci.org/en/2017/09/26/very-late-thrombosis-in-bioresorbable-scaffolds/" title="Read more" >...</a>

¿Beneficio adicional del bypass radial en la cirugía de revascularización miocárdica?

Additional Benefit from Radial Artery Graft in Myocardial Revascularization Surgery

Used to different extents according to institution, surgeon, and historical time, the radial artery graft is yet to prove whether it can improve the outcomes of myocardial revascularization surgery&nbsp;when added to a single or bilateral internal thoracic artery graft. The ART (Arterial Revascularization Trial) was designed to compare survival after bilateral vs. single left internal<a href="https://solaci.org/en/2017/09/21/additional-benefit-from-radial-artery-graft-in-myocardial-revascularization-surgery/" title="Read more" >...</a>

bioresorbable-vascular-scaffold

Polymer-Free DES Also Show Efficacy in Anticoagulated Patients with High Risk for Bleeding

Patients who receive chronic anticoagulation therapy and then undergo angioplasty are frequently discharged on a triple anti-thrombotic scheme that usually includes&nbsp;aspirin, clopidogrel, and warfarin. The optimal duration of this indication remains unclear, particularly for patients at high bleeding risk. According to expert consensus, patients receiving chronic anticoagulation may receive from 1 to 12&nbsp;months of dual<a href="https://solaci.org/en/2017/09/08/polymer-free-des-also-show-efficacy-in-anticoagulated-patients-with-high-risk-for-bleeding/" title="Read more" >...</a>

Los marcapasos post TAVI aumentan los costos pero no los eventos adversos

Pacemaker Implantation After TAVI Raises Costs But Not the Incidence of Adverse Events

This new meta-analysis did not manage to prove whether permanent pacemaker implantation after transcatheter aortic valve replacement&nbsp;(TAVR) raises the rates of mortality, infarction, or stroke. Implantation could only be associated to a lesser recovery of ventricular function after the procedure, something that had already been observed in previous studies. Patients who required a pacemaker undoubtedly<a href="https://solaci.org/en/2017/09/07/pacemaker-implantation-after-tavi-raises-costs-but-not-the-incidence-of-adverse-events/" title="Read more" >...</a>

La angioplastia “ad hoc” durante el TAVI no impacta en su seguridad ni en resultados a largo plazo

“Ad Hoc” PCI during TAVR: No Impact on Safety or Long Term Outcomes

According to a recent study published in&nbsp;Circulation Cardiovascular Interventions, screening for coronary artery disease&nbsp;(CAD) with an invasive coronary angiography&nbsp; (as part of the protocol prior TAVR) &nbsp;and performing PCI and TAVR&nbsp;in the same session, has no impact on periprocedural safety or on long term outcomes. Study outcomes offer new hope, especially as regards using TAVR<a href="https://solaci.org/en/2017/09/06/ad-hoc-pci-during-tavr-no-impact-on-safety-or-long-term-outcomes/" title="Read more" >...</a>

La estrategia invasiva precoz beneficia a los pacientes de alto riesgo

Early Invasive Strategy Benefits High-Risk Patients

Early angiography is not associated with a reduction in mortality compared with a more delayed invasive strategy in patients with non-ST-elevation acute coronary syndrome (NSTE-ACS). However, a new meta-analysis published by The&nbsp;Lancet supports the idea that certain high-risk patients would benefit from it. Patients with elevated cardiac biomarkers, a high GRACE score, diabetes, or advanced<a href="https://solaci.org/en/2017/09/01/early-invasive-strategy-benefits-high-risk-patients/" title="Read more" >...</a>

Sorpresivo hallazgo en diabetes y permeabilidad de los bypass

Striking Finding on Diabetes and Bypass Graft Patency

The higher rate of restenosis in the diabetic&nbsp;population is historic and has been reproduced in all studies and with all kinds of stents, but it was only after the FREEDOM trial when we found out about the higher infarction rate with&nbsp;PCI&nbsp;compared to surgery. This is why 50% of patients undergoing&nbsp;CABG&nbsp;are diabetic. Apart from the above<a href="https://solaci.org/en/2017/09/01/striking-finding-on-diabetes-and-bypass-graft-patency/" title="Read more" >...</a>

¿Debemos comenzar a utilizar IVUS en las CTO?

Should We Begin to Use IVUS in CTO?

Courtesy of Dr. Carlos&nbsp;Fava. Currently,&nbsp;chronic total occlusions&nbsp;(CTO)&nbsp;are one of the obstacles that&nbsp;coronary angioplasties must overcome, particularly with the development of&nbsp;drug-eluting stents (DES)&nbsp;and new devices and strategies for these challenging lesions. However, there is little information on the safety, efficacy, and real clinical benefit of implanting stents of over 60&nbsp;mm (known as full metal jackets, FMJ).<a href="https://solaci.org/en/2017/08/28/should-we-begin-to-use-ivus-in-cto/" title="Read more" >...</a>

presentaciones ProEducar

See All ProEducar “José Gabay” Course (Eighth Edition) Presentations

We are deeply thankful to all interventional physicians who, motivated by their great scientific and educational vocation, presented their works at the “José Gabay” Course and actively collaborated in training and providing updated concepts for the next generations of interventional cardiologists. Read and/or download the presentations below: &nbsp; Module&nbsp;I: Fundamentals and Basic Elements. Álvarez, José.<a href="https://solaci.org/en/2017/08/22/see-all-proeducar-jose-gabay-course-eighth-edition-presentations/" title="Read more" >...</a>

La ATP de la femoral común comienza a ser una opción válida

Common Femoral PCI Becomes a Valid Alternative

Gentileza del Dr. Carlos Fava. The common femoral artery has always been treated with surgery. Thanks to the development of new generation stents and the advancement of percutaneous intervention, common femoral lesions are currently being treated with PCI. However, data on the safety of PCI vs. surgery, remain unavailable.&nbsp; The TECCO is multicenter study, randomized<a href="https://solaci.org/en/2017/08/17/common-femoral-pci-becomes-a-valid-alternative/" title="Read more" >...</a>

Top